Telix Pharmaceuticals: Strong Revenue Performance and Strategic Positioning Support Buy Rating

In a report released yesterday, Tara Bancroft from TD Cowen maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$35.00.

Tara Bancroft’s rating is based on Telix Pharmaceuticals’ strong revenue performance and strategic positioning in the market. The company reported a total revenue of $390 million for the first half, which exceeded expectations and demonstrated significant year-over-year growth. This was largely driven by the success of Illuccix, which showed robust sales figures, and the contribution from RLS revenues.
Despite potential pricing pressures due to the loss of transitional pass-through status for Illuccix, Telix has reaffirmed its revenue guidance for 2025. The anticipated launch of Gozellix, with its new permanent HCPCS code, is expected to mitigate some of the pricing impacts and support future growth. Bancroft anticipates that the switch to Gozellix will lead to stable sales in the prostate cancer diagnostics franchise, further supporting the Buy rating.

Bancroft covers the Healthcare sector, focusing on stocks such as Urogen Pharma, Merus, and Telix Pharmaceuticals. According to TipRanks, Bancroft has an average return of 0.4% and a 44.23% success rate on recommended stocks.

In another report released on August 6, Jefferies also maintained a Buy rating on the stock with a A$32.70 price target.